- HK$36.60bn
- HK$21.56bn
- CNY17.70bn
Brief: Pfizer Enters Into Exclusive Licensing Agreement With 3SBio
Brief: 3Sbio Enters Into License Agreement With Pfizer
Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Brief: 3Sbio Says 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation By NMPA
Brief: 3SBIO Announces Final Dividend Of HKD25 Cents Per Share
Brief: 3SBio Announces Cooperation With Duality Biologics In Respect Of Her2 Adc Drug
Brief: 3SBio Announces Cooperation Between Shenyang Sunshine And Sunshine Lake Pharma
Brief: 3SBio Says CFO Increased Shareholding In Co
Brief: 3SBio Says Unit Entered Exclusive Commercialization Cooperation Agreement
Brief: 3SBio Declares Interim Net Profit Attributable Of RMB1,089.9 Mln
Brief: 3SBio Says Unit Entered Into Cooperation Agreement With Hybio Pharmaceutical
Brief: 3Sbio Says Recombinant Human Thrombopoietin Injection Approved For Pediatric ITP Indication
Brief: 3SBio Declares Final Dividend Of HK$25 Cents Per Share
Brief: 3Sbio Says Mandi Foam Approved For Market Launch By Nmpa
Brief: 3Sbio Says Withdrawal Of Listing Of Zero Coupon Convertible Bonds Due 2025
Brief: 3Sbio Says HY Net Profit Attributable Increased By 1.4% To RMB980.6 Million
Brief: 3Sbio Says He Xiang Appointed As Chief Financial Officer
Brief: 3Sbio Says Narfuraphine Hydrochloride Orally Disintegrating Tablets In Japan Approved For Market Launch
Brief: 3Sbio Says First Patient Enrolled In Trial Of Phase III Clinical Study Of Recombinant Human Thrombopoietin Injection